Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Study sponsor: Arrowhead Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-12Actual
Enrollment · participants79Actual
Source updated2026-01-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.